<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02392026</url>
  </required_header>
  <id_info>
    <org_study_id>MG1401</org_study_id>
    <nct_id>NCT02392026</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of Metronidazole Gel 1.3%</brief_title>
  <official_title>A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Metronidazole Vaginal Gel 1.3% in Adolescent Female Subjects With Bacterial Vaginosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan Sales, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter, open-label study to evaluate safety and tolerability of Metronidazole Vaginal
      Gel in females 12 to &lt;18 years for the treatment of bacterial vaginosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multicenter, open-label study to evaluate safety and tolerability of Metronidazole Vaginal
      Gel 1.3% when administered as a single dose in adolescent females (aged 12 to &lt;18 years) for
      the treatment of bacterial vaginosis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 11, 2015</start_date>
  <completion_date type="Actual">November 30, 2016</completion_date>
  <primary_completion_date type="Actual">October 31, 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with treatment-emergent adverse events (AEs), serious AEs, treatment-related AEs and AEs leading to study discontinuation after Metronidazole Vaginal Gel is administered in post-menarcheal, adolescent females with bacterial vaginosis.</measure>
    <time_frame>up to 10 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects reporting presence of daily vaginal discharge and/or odor following single dose administration of Metronidazole Vaginal Gel 1.3%assessment of the presence of vaginal discharge and odor following single dose administration.</measure>
    <time_frame>up to 10 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Vaginosis, Bacterial</condition>
  <arm_group>
    <arm_group_label>Metronidazole Gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metronidazole Vaginal Gel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole Gel</intervention_name>
    <description>Metronidazole Vaginal Gel 1.3% administered via applicator</description>
    <arm_group_label>Metronidazole Gel</arm_group_label>
    <other_name>Metro Gel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provide written assent and parent/legal guardian informed consent and authorization to
             disclose protected health information.

          -  Post-menarcheal, adolescent female, 12 to &lt;18 years of age at time of
             Screening/Baseline Visit (Day 1).

          -  In good general health at Screening visit with no known medical conditions that, in
             the Investigator's opinion, may interfere with study participation.

          -  Has negative urine pregnancy test result prior to study treatment initiation.

          -  Has clinical diagnosis of bacterial vaginosis.

          -  Agree to abstain from sexual intravaginal intercourse for study duration.

          -  Willing to avoid alcohol ingestion for 24 hours after administration of test article.

          -  Agree to refrain from use of intravaginal products for duration of study (e.g.
             lubricated condoms, tampons, diaphragms, spermicides, feminine deodorant sprays,
             douches). Intravaginal Uterine Device (IUD) use is acceptable as long as it has been
             in place for 30 days prior to study enrollment.

          -  Willing and able to participate in study, make required visits to the study center,
             and comply with all study requirements including concomitant medication and other
             treatment restrictions.

        Exclusion Criteria:

          -  Pregnant, lactating, or planning to become pregnant during study period.

          -  Currently menstruating or anticipate onset of menses during first 9 days of the study.

          -  Experience a clinically important medical event with 90 days of Screening/Baseline
             Visit (Day 1).

          -  Evidence of other infectious causes of vulvovaginal infection or condition that in the
             Investigator's opinion would confound the interpretation of the study results.

          -  Severe symptoms of dysuria and/or pruritus, burning or irritation in vulvovaginal
             area.

          -  Received systemic or intravaginal antifungal, antibacterial or antiparasitic drugs
             within 14 days of Screening/Baseline visit (Day 1). Antiviral therapies
             (non-intravaginal) are acceptable.

          -  Has taken disulfiram or systemic corticosteroids (oral or injected) within 14 days of
             Screening/Baseline Visit (Day 1).

          -  Had sexual intravaginal intercourse within 24 hours of Screening/Baseline (Day 1).

          -  Demonstrated previous hypersensitivity to metronidazole, either orally or topically
             administered, or any form of parabens or benzyl alcohol.

          -  Known primary or secondary immunodeficiency condition/syndrome.

          -  Being treated or planning to be treated during the study period for cervical
             intraepithelial neoplasia (CIN) or cervical carcinoma.

          -  Using anticoagulation therapy with Coumadin (warfarin).

          -  Previously treated with test article under this protocol.

          -  Participate in an experimental drug/device trial within the last 30 days before
             Screening/Baseline Visit (Day 1).

          -  Is judged by the Investigator to be unsuitable for any reason.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gina Giannantoni-Ibelli, MS</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Allergan Research Site #318</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergan Research Site #324</name>
      <address>
        <city>Paramount</city>
        <state>California</state>
        <zip>90723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergan Research Site #315</name>
      <address>
        <city>Bardstown</city>
        <state>Kentucky</state>
        <zip>40004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergan Research Site #314</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergan Research Site #319</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergan Research Site #322</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergan Research Site #321</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergan Research Site #316</name>
      <address>
        <city>Irving</city>
        <state>Texas</state>
        <zip>75062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2015</study_first_submitted>
  <study_first_submitted_qc>March 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2015</study_first_posted>
  <disposition_first_submitted>October 19, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>October 19, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">October 23, 2017</disposition_first_posted>
  <last_update_submitted>October 19, 2017</last_update_submitted>
  <last_update_submitted_qc>October 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaginal Diseases</mesh_term>
    <mesh_term>Vaginosis, Bacterial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metronidazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

